LUND, Sweden—Active Biotech AB presented results from exploratory preclinical studies at the Keystone Symposia "Molecular and Cellular Biology of Immune Escape in Cancer" held in Keystone, Colo., Feb. 7-12.
The study, "Combining tumor-targeted superantigens with anti-CTLA-4 results in synergistic anti-tumor effects in B16 tumor bearing mice,” demonstrates that TTS therapy can be further enhanced by specifically modulating the immune response in this experimental model. The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase III clinical trials for renal cell cancer. The primary endpoint is overall survival and results from these studies are expected first half of 2011.
